/Companies

Harmony Biosciences

NASDAQ: HRMYUnicorn · $1.4B

Northbrook, US · Founded 2017 · Delaware corporation · 341 employees on LinkedIn · 8 known investors

Find your way into Harmony Biosciences

116 people in our graph share verified history with the Harmony Biosciences team — schools, employers, funds. One of them is your warm intro.

Richard Gasterunlockedknows Jeffrey M. Dayno, M.D. · together at Harmony Biosciences (overlapped)
×6knows the team · via Egalet Corporation
knows the team · via ViroPharma Incorporated ;-)
×4knows the team · via Cephalon

Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases. The company serves patients, families, and advocates in the rare disease community through novel drug development and patient-centered approaches.

Founders & leadership

Harmony Biosciences was founded in 2017 by Jeffrey Aronin.

JAJeffrey Aronin
Jeffrey AroninFounder
JMJeffrey M. Dayno, M.D.
Jeffrey M. Dayno, M.D.President and Chief Executive OfficerDr. Dayno is a neurologist with 10 years of clinical and academic medicine experience and over 25 years in the pharmaceutical industry, including leadership roles at Merck & Co., Cephalon, and ViroPharma where he oversaw clinical, regulatory, and medical affairs teams. He earned his M.D. from Temple University School of Medicine and completed residency training in Neurology at Temple University Hospital and a fellowship in Stroke and Cerebrovascular Disorders at Henry Ford Hospital.
PMPatrick Morris
Patrick MorrisSecretary and Treasurer
RR
Robert RepellaDirector and Chief Executive Officer
DP
Darien ParhadChief Financial Officer

Board

ARAaron Royston
Aaron RoystonBoard Of Directors2017–2020Managing Partner at venBio Partners
DA
Dr. Andreas WickiBoard director
JNJack Nielsen
Jack NielsenBoard MemberManaging Partner at Vivo Capital
AGAntonio Gracias
Antonio GraciasBoard directorFounder, Chief Executive Officer & Chief Investment Officer at Valor Equity Partners
ME
Martin EdwardsBoard director
JSJuan Sabater
Juan SabaterBoard directorPartner and Co-President at Valor Equity Partners
WG
Wilbur Gantz IIIBoard director

Investors · 8

Reported raises · per SEC filings

Form D private placements

$345M disclosed across 3 rounds · 2017–2019

▶$50MraisedAug 2019 · 30 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • JACK BECH NIELSENDirector
  • MARTIN EDWARDSDirector
  • AARON ROYSTONDirector
  • DR. ANDREAS WICKIDirector
  • WILBUR GANTZ, IIIDirector
  • OCTAGON CAPITAL GROUP, LLCPromoter
  • JUAN SABATERDirector
  • JOHN JACOBSExecutive Officer, Director
  • JOHN VITTORIAExecutive Officer
  • ANDREW SERAFINExecutive Officer
  • JEFFREY ARONINDirector
  • ANTONIO GRACIASDirector
  • PATRICK MORRISExecutive Officer
Offering amount
$50M
Amount sold
$50M
Minimum investment
$14K
Sales commissions
$1M
Placement agents
OCTAGON CAPITAL GROUP, LLC
First sale
Aug 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedJan 2018 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick MorrisExecutive Officer
  • Jeffrey AroninDirector
  • Aaron RoystonDirector
  • Dr. Andreas WickiDirector
  • Jack NielsenDirector
  • Robert RepellaExecutive Officer, Director
  • Antonio GraciasDirector
  • Martin EdwardsDirector
  • Juan SabaterDirector
  • Wilbur Gantz IIIDirector
  • Darien ParhadExecutive Officer
Offering amount
$25M
Amount sold
$25M
First sale
Jan 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$270MraisedOct 2017 · 29 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick MorrisExecutive Officer
  • Wilbur Gantz IIIDirector
  • Octagon Capital Group, LLCPromoter
  • Darien ParhadExecutive Officer
  • Juan SabaterDirector
  • Martin EdwardsDirector
  • Aaron RoystonDirector
  • Jeffrey AroninDirector
  • Dr. Andreas WickiDirector
  • Jack Bech NielsenDirector
  • Robert RepellaDirector
  • Antonio GraciasDirector
Offering amount
$270M
Amount sold
$270M
Minimum investment
$50K
Sales commissions
$5.9M
Placement agents
Octagon Capital Group, LLC
First sale
Sep 2017
Incorporated
Limited Liability Company, Illinois, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$1.4Bvaluation at IPOAug 2020 · $24.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 1

by search overlap

Companies competing with Harmony Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Harmony Biosciences do?
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases. The company serves patients, families, and advocates in the rare disease community through novel drug development and patient-centered approaches.
Who founded Harmony Biosciences?
Harmony Biosciences was founded by Jeffrey Aronin in 2017.
Who are Harmony Biosciences's investors?
Harmony Biosciences's investors include Aisling Capital, Paragon Biosciences LLC, Pivotal Life Sciences, Valor Equity Partners, venBio Partners, Novo Holdings, venBio Global Strategic, Vivo Capital.
How much funding has Harmony Biosciences raised?
Harmony Biosciences has disclosed $345M raised across 3 rounds.
Where is Harmony Biosciences headquartered?
Harmony Biosciences is headquartered in Northbrook, US.